182 related articles for article (PubMed ID: 24596388)
21. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
[TBL] [Abstract][Full Text] [Related]
22. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1.
Wulf GM; Ryo A; Wulf GG; Lee SW; Niu T; Petkova V; Lu KP
EMBO J; 2001 Jul; 20(13):3459-72. PubMed ID: 11432833
[TBL] [Abstract][Full Text] [Related]
23. Effect of Pin1 inhibitor juglone on proliferation, migration and angiogenic ability of breast cancer cell line MCF7Adr.
Hu YG; Shen YF; Li Y
J Huazhong Univ Sci Technolog Med Sci; 2015 Aug; 35(4):531-534. PubMed ID: 26223922
[TBL] [Abstract][Full Text] [Related]
24. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
Menendez JA; Vellon L; Lupu R
Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
[TBL] [Abstract][Full Text] [Related]
25. Prolyl isomerase Pin1 negatively regulates the stability of SUV39H1 to promote tumorigenesis in breast cancer.
Khanal P; Kim G; Lim SC; Yun HJ; Lee KY; Choi HK; Choi HS
FASEB J; 2013 Nov; 27(11):4606-18. PubMed ID: 23934277
[TBL] [Abstract][Full Text] [Related]
26. Targeting peptidyl-prolyl isomerase pin1 to inhibit tumor cell aggressiveness.
Beretta GL; De Cesare M; Albano L; Magnifico A; Carenini N; Corna E; Perego P; Gatti L
Tumori; 2016; 102(2):144-9. PubMed ID: 26917410
[TBL] [Abstract][Full Text] [Related]
27. PIN1 inhibition suppresses osteoclast differentiation and inflammatory responses.
Cho YA; Jue SS; Bae WJ; Heo SH; Shin SI; Kwon IK; Lee SC; Kim EC
J Dent Res; 2015 Feb; 94(2):371-80. PubMed ID: 25512367
[TBL] [Abstract][Full Text] [Related]
28. Pin1 modulates chemo-resistance by up-regulating FoxM1 and the involvements of Wnt/β-catenin signaling pathway in cervical cancer.
Wang T; Liu Z; Shi F; Wang J
Mol Cell Biochem; 2016 Feb; 413(1-2):179-87. PubMed ID: 26820938
[TBL] [Abstract][Full Text] [Related]
29. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
[TBL] [Abstract][Full Text] [Related]
30. Rhein exhibits antitumorigenic effects by interfering with the interaction between prolyl isomerase Pin1 and c-Jun.
Cho JH; Chae JI; Shim JH
Oncol Rep; 2017 Mar; 37(3):1865-1872. PubMed ID: 28184937
[TBL] [Abstract][Full Text] [Related]
31. PI3-kinase/p38 kinase-dependent E2F1 activation is critical for Pin1 induction in tamoxifen-resistant breast cancer cells.
Lee KY; Lee JW; Nam HJ; Shim JH; Song Y; Kang KW
Mol Cells; 2011 Jul; 32(1):107-11. PubMed ID: 21573702
[TBL] [Abstract][Full Text] [Related]
32. Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis.
Wulf G; Garg P; Liou YC; Iglehart D; Lu KP
EMBO J; 2004 Aug; 23(16):3397-407. PubMed ID: 15257284
[TBL] [Abstract][Full Text] [Related]
33. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
Menendez JA; Vellon L; Lupu R
Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
[TBL] [Abstract][Full Text] [Related]
34. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
35. COT phosphorylates prolyl-isomerase Pin1 to promote tumorigenesis in breast cancer.
Kim G; Khanal P; Kim JY; Yun HJ; Lim SC; Shim JH; Choi HS
Mol Carcinog; 2015 Jun; 54(6):440-8. PubMed ID: 24265246
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-22 promotes epithelial cell transformation and breast tumorigenesis via MAP3K8 activation.
Kim K; Kim G; Kim JY; Yun HJ; Lim SC; Choi HS
Carcinogenesis; 2014 Jun; 35(6):1352-61. PubMed ID: 24517997
[TBL] [Abstract][Full Text] [Related]
37. All-
Kim G; Bhattarai PY; Oh CH; Choi HS
Anticancer Res; 2019 Dec; 39(12):6537-6546. PubMed ID: 31810919
[TBL] [Abstract][Full Text] [Related]
38. CD147 knockdown improves the antitumor efficacy of trastuzumab in HER2-positive breast cancer cells.
Xiong L; Ding L; Ning H; Wu C; Fu K; Wang Y; Zhang Y; Liu Y; Zhou L
Oncotarget; 2016 Sep; 7(36):57737-57751. PubMed ID: 27363028
[TBL] [Abstract][Full Text] [Related]
39. A suppressive role of the prolyl isomerase Pin1 in cellular apoptosis mediated by the death-associated protein Daxx.
Ryo A; Hirai A; Nishi M; Liou YC; Perrem K; Lin SC; Hirano H; Lee SW; Aoki I
J Biol Chem; 2007 Dec; 282(50):36671-81. PubMed ID: 17938171
[TBL] [Abstract][Full Text] [Related]
40. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
